TC LPA5 4LPA5 receptor antagonist CAS# 1393814-38-4 |
2D Structure
- Nadifloxacin
Catalog No.:BCC4804
CAS No.:124858-35-1
- Calcipotriol monohydrate
Catalog No.:BCC1445
CAS No.:147657-22-5
- Halobetasol Propionate
Catalog No.:BCC4664
CAS No.:66852-54-8
- Dihydroartemisinin
Catalog No.:BCN6264
CAS No.:71939-50-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1393814-38-4 | SDF | Download SDF |
PubChem ID | 66552906 | Appearance | Powder |
Formula | C23H23ClN2O3 | M.Wt | 410.89 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | 5-(3-chloro-4-cyclohexylphenyl)-1-(3-methoxyphenyl)pyrazole-3-carboxylic acid | ||
SMILES | COC1=CC=CC(=C1)N2C(=CC(=N2)C(=O)O)C3=CC(=C(C=C3)C4CCCCC4)Cl | ||
Standard InChIKey | BNALUYKEGYUHQC-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C23H23ClN2O3/c1-29-18-9-5-8-17(13-18)26-22(14-21(25-26)23(27)28)16-10-11-19(20(24)12-16)15-6-3-2-4-7-15/h5,8-15H,2-4,6-7H2,1H3,(H,27,28) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | LPA5 receptor antagonist (IC50 = 0.8 μM in LPA5-RH7777 cells). Inhibits LPA-induced aggregation of isolated human platelets. Exhibits selectivity for LPA5 against 80 other screened targets. |
TC LPA5 4 Dilution Calculator
TC LPA5 4 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4337 mL | 12.1687 mL | 24.3374 mL | 48.6748 mL | 60.8435 mL |
5 mM | 0.4867 mL | 2.4337 mL | 4.8675 mL | 9.735 mL | 12.1687 mL |
10 mM | 0.2434 mL | 1.2169 mL | 2.4337 mL | 4.8675 mL | 6.0844 mL |
50 mM | 0.0487 mL | 0.2434 mL | 0.4867 mL | 0.9735 mL | 1.2169 mL |
100 mM | 0.0243 mL | 0.1217 mL | 0.2434 mL | 0.4867 mL | 0.6084 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- KPT-330
Catalog No.:BCC4446
CAS No.:1393477-72-9
- Thiostrepton
Catalog No.:BCC7621
CAS No.:1393-48-2
- KN-93
Catalog No.:BCC1683
CAS No.:139298-40-1
- MDL 100907
Catalog No.:BCC7877
CAS No.:139290-65-6
- Zolmitriptan
Catalog No.:BCC5062
CAS No.:139264-17-8
- H2L5186303
Catalog No.:BCC6315
CAS No.:139262-76-3
- Fmoc-Lys-OH.HCl
Catalog No.:BCC3512
CAS No.:139262-23-0
- G-36
Catalog No.:BCC6283
CAS No.:1392487-51-2
- Musellarin C
Catalog No.:BCN7004
CAS No.:1392476-33-3
- Musellarin B
Catalog No.:BCN7192
CAS No.:1392476-32-2
- 3,4-Dihydroxy-2-O-methylanigorufone
Catalog No.:BCN7182
CAS No.:1392307-42-4
- Dodonaflavonol
Catalog No.:BCN6862
CAS No.:1392213-93-2
- Guan-fu base A
Catalog No.:BCN8491
CAS No.:1394-48-5
- Tiotropium Bromide hydrate
Catalog No.:BCC4585
CAS No.:139404-48-1
- GNE-317
Catalog No.:BCC5655
CAS No.:1394076-92-6
- 8alpha-Hydroxyhirsutinolide
Catalog No.:BCN7111
CAS No.:1394156-45-6
- Boc-Cysteinol(Bzl)
Catalog No.:BCC3043
CAS No.:139428-96-9
- 6-O-apiosyl-5-O-Methylvisammioside
Catalog No.:BCN7858
CAS No.:139446-82-5
- Methyl 2-(((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)amino)-3-nitrobenzoate
Catalog No.:BCC9033
CAS No.:139481-28-0
- Ethyl 2-ethoxy-1-[(2'-cyanobiphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylate
Catalog No.:BCC8970
CAS No.:139481-41-7
- Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate
Catalog No.:BCC9032
CAS No.:139481-44-0
- Candesartan ethyl ester
Catalog No.:BCC8901
CAS No.:139481-58-6
- Candesartan
Catalog No.:BCC2558
CAS No.:139481-59-7
- Candesartan methyl ester
Catalog No.:BCC8902
CAS No.:139481-69-9
Selective non-lipid modulator of LPA5 activity in human platelets.[Pubmed:22801643]
Bioorg Med Chem Lett. 2012 Aug 15;22(16):5239-43.
Lysophosphatidic acid (LPA) is a potent activator of human platelets in vitro. Recently, the G protein-coupled receptor LPA5/GPR92 has been identified to be the relevant LPA receptor responsible for the activation of human platelets by LPA. In a high-throughput screening campaign we identified a diphenyl pyrazole carboxylic acid as a small-molecule inhibitor for LPA5. Confirmation for the specificity of this small molecule was achieved in human platelets as the relevant cellular in vitro model. We could confirm using antagonists for alternative LPA receptors that we identified in our work the first non-lipid, small-molecule inhibitor for LPA5/GPR92 specifically inhibiting LPA-mediated platelet activation in vitro.